Dell Technologies Inc vs Erasca Inc. Common Stock — how do they compare? Dell Technologies Inc trades at $581.22 (market cap $365.31B), while Erasca Inc. Common Stock trades at $16.08 (market cap $5.40B). The key difference: Dell Technologies Inc is far larger — about 67.7× Erasca Inc. Common Stock's market cap, and Dell Technologies Inc pays a 0.44% dividend while Erasca Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dell Technologies Inc for 57 Days and Erasca Inc. Common Stock for 0 Days on average.
| DELL | ERAS | |
|---|---|---|
Market Cap | $365.31B | $5.40B |
Volume | 5,121,365 | 9,533,185 |
Sector | Technology | Health |
52-Week High | $588.67 | $22.47 |
52-Week Low | $111.10 | $2.20 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | $388.20B | $5.18B |
Dividend Yield | 0.44% | — |
Signals from Pluang's Aura AI — not financial advice
Dell Technologies (DELL) trades at $575.33, down 0.63% on the day, but maintains a bullish technical trend with strong support near $566. The stock is buoyed by robust AI server demand, with Q2 2026 EPS beating estimates by 43% and fiscal 2027 revenue guidance raised to approximately $192 billion. Recent news highlights a 20% dividend increase and a $74 billion AI server backlog, fueling investor optimism.
Outlook remains positive given explosive AI-driven growth, but risks include execution on massive orders and competitive pressures. Analysts are largely bullish with a $566.35 consensus target, though the current price slightly exceeds it. Shareholders should monitor margin sustainability and debt levels amid rapid expansion.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses
Read more on DELL →Erasca is a biotechnology company developing precision medicines for cancer. Its programs target genetic drivers of tumor growth.
Read more on ERAS →